Jeffery Auletta, MD

Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.

CancerNetwork® spoke with Jeffery Auletta, MD, about how the National Marrow Donor Program/Be The Match is using research initiatives to expand eligibility for stem cell transplants in for patient with acute leukemias and myelodysplastic syndrome.